CG
BBIO icon

Cutler Group’s BridgeBio Pharma BBIO Stock Holding History

Cutler Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,300
Closed -$13K – 3565
2023
Q1 		$13K Buy
+7,300
New +$85.1K ﹤0.01% 2142
2022
Q4 		– Sell
-3,400
Closed -$6K – 4381
2022
Q3 		$6K Sell
3,400
-7,400
-69% -$76.9K ﹤0.01% 3458
2022
Q2 		$12K Sell
10,800
-20,100
-65% -$168K ﹤0.01% 3040
2022
Q1 		$20K Sell
30,900
-62,100
-67% -$637K ﹤0.01% 3051
2021
Q4 		$126K Buy
93,000
+80,800
+662% +$3.42M 0.01% 1675
2021
Q3 		$19K Buy
12,200
+1,100
+10% +$59K ﹤0.01% 3371
2021
Q2 		$16K Buy
11,100
+4,400
+66% +$251K ﹤0.01% 3481
2021
Q1 		$10K Buy
+6,700
New +$438K ﹤0.01% 3786
2020
Q4 		– Sell
-1,000
Closed -$2K – 4789
2020
Q3 		$2K Sell
1,000
-28,900
-97% -$909K ﹤0.01% 3988
2020
Q2 		$66K Buy
29,900
+18,400
+160% +$560K ﹤0.01% 1559
2020
Q1 		$42K Buy
+11,500
New +$357K ﹤0.01% 1830

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cutler Group's BBIO Position: Q4 2023 in Review

Cutler Group sold out of BridgeBio Pharma (BBIO) in Q4 2023, closing a stake of 300 shares — an estimated $7K sold.

Cutler Group first reported a position in BBIO in Q1 2020 and held it in 10 quarters. The position peaked at $493K in Q4 2021. 247 funds tracked by Wall St. Rank hold BBIO as of Q4 2023.

  • Cutler Group reported no remaining BridgeBio Pharma position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 300 BridgeBio Pharma shares in Q4 2023, an estimated $7K.
  • Cutler Group first reported a position in BridgeBio Pharma in Q1 2020 and held it in 10 quarters.
  • Cutler Group's BridgeBio Pharma position peaked at $493K in Q4 2021.
  • 247 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.